

Intratumoral heterogeneity and *TERT* promoter progressive/higher-grade meningiomas

Oncotarget

8, 109228-109237

DOI: [10.18632/oncotarget.22650](https://doi.org/10.18632/oncotarget.22650)

Citation Report

#	ARTICLE	IF	CITATIONS
1	High-grade meningiomas: biology and implications. <i>Neurosurgical Focus</i> , 2018, 44, E2.	1.0	31
2	Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. <i>Acta Neuropathologica</i> , 2018, 135, 955-963.	3.9	109
3	New molecular targets in meningiomas: the present and the future. <i>Current Opinion in Neurology</i> , 2018, 31, 740-746.	1.8	13
4	De novo and secondary anaplastic meningiomas: natural history, prognosis, and the TERT promoter. <i>Neuro-Oncology</i> , 2018, 20, 1009-1010.	0.6	2
5	TERT, the target?. <i>Neuro-Oncology</i> , 2018, 20, 1561-1562.	0.6	0
6	Towards Molecular Classification of Meningioma: Evolving Treatment and Diagnostic Paradigms. <i>World Neurosurgery</i> , 2018, 119, 366-373.	0.7	45
7	TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas. <i>Journal of Neuro-Oncology</i> , 2018, 139, 671-678.	1.4	51
8	<i>TERT</i> promoter mutations are associated with poor prognosis and cell immortalization in meningioma. <i>Neuro-Oncology</i> , 2018, 20, 1584-1593.	0.6	88
9	TERT Alterations in Progressive Treatment-Resistant Meningiomas. <i>Neurosurgery</i> , 2018, 65, 66-68.	0.6	8
10	DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome. <i>Acta Neuropathologica</i> , 2018, 136, 779-792.	3.9	66
11	Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 21715-21726.	3.3	122
12	Genomic Analysis of Posterior Fossa Meningioma Demonstrates Frequent AKT1 E17K Mutations in Foramen Magnum Meningiomas. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2019, 80, 562-567.	0.4	18
13	Advances in multidisciplinary therapy for meningiomas. <i>Neuro-Oncology</i> , 2019, 21, i18-i31.	0.6	102
14	Prediction of High-Grade Histology and Recurrence in Meningiomas Using Routine Preoperative Magnetic Resonance Imaging: A Systematic Review. <i>World Neurosurgery</i> , 2019, 128, 174-181.	0.7	33
15	TERT Promoter Mutation Spatial Heterogeneity in a Metastatic Follicular Thyroid Carcinoma: Implications for Clinical Work-Up. <i>Endocrine Pathology</i> , 2019, 30, 246-248.	5.2	20
16	Mutational patterns and regulatory networks in epigenetic subgroups of meningioma. <i>Acta Neuropathologica</i> , 2019, 138, 295-308.	3.9	74
17	Intraoperative quantification of meningioma cell proliferation potential using rapid flow cytometry reveals intratumoral heterogeneity. <i>Cancer Medicine</i> , 2019, 8, 2793-2801.	1.3	7
18	Evolutionary Trajectories of IDHWT Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis. <i>Cancer Cell</i> , 2019, 35, 692-704.e12.	7.7	172

#	ARTICLE	IF	CITATIONS
19	Biomarkers in tumors of the central nervous system – a review. <i>Apmsis</i> , 2019, 127, 265-287.	0.9	9
20	Molecular alterations in meningiomas: Literature review. <i>Clinical Neurology and Neurosurgery</i> , 2019, 176, 89-96.	0.6	28
21	Role of a Promoter Mutation in TERT in Malignant Transformation of Pleomorphic Xanthoastrocytoma. <i>World Neurosurgery</i> , 2019, 126, 624-630.	0.7	10
22	TERT promoter methylation is significantly associated with TERT upregulation and disease progression in pituitary adenomas. <i>Journal of Neuro-Oncology</i> , 2019, 141, 131-138.	1.4	19
23	The prognostic significance of TERT promoter mutations in meningioma: a systematic review and meta-analysis. <i>Journal of Neuro-Oncology</i> , 2019, 142, 1-10.	1.4	31
24	Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups. <i>Journal of Neuro-Oncology</i> , 2019, 141, 327-335.	1.4	72
25	Telomerase activity, TERT expression, hTERT promoter alterations, and alternative lengthening of the telomeres (ALT) in meningiomas – a systematic review. <i>Neurosurgical Review</i> , 2020, 43, 903-910.	1.2	25
26	Forkhead box M1 (FOXM1) transcription factor is a key oncogenic driver of aggressive human meningioma progression. <i>Neuropathology and Applied Neurobiology</i> , 2020, 46, 125-141.	1.8	33
27	A Clinical Overview of Telomerase-Associated Aberrancies in Follicular Thyroid Tumors as Diagnostic and Prognostic Markers: Tert Alert!. <i>Scandinavian Journal of Surgery</i> , 2020, 109, 187-192.	1.3	7
28	In Reply: Retention of ATRX and DAXX Expression in Meningiomas. <i>Neurosurgery</i> , 2020, 86, E244-E246.	0.6	6
29	Letter: Parasagittal/Falcine Tumor Location Strongly Predicts Human Telomerase Reverse Transcriptase Promoter Mutations in High-Grade Meningiomas. <i>Neurosurgery</i> , 2020, 86, E362-E365.	0.6	5
30	High Tumor Mitochondrial DNA Content Correlates With an Improved Patient's Outcome in WHO Grade III Meningioma. <i>Frontiers in Oncology</i> , 2020, 10, 542294.	1.3	2
31	Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic. <i>Acta Neuropathologica Communications</i> , 2020, 8, 171.	2.4	58
32	Mitotic and Proliferative Indices in WHO Grade III Meningioma. <i>Cancers</i> , 2020, 12, 3351.	1.7	5
33	Prognostic Model That Predicts Benefits of Adjuvant Radiotherapy in Patients With High Grade Meningioma. <i>Frontiers in Oncology</i> , 2020, 10, 568079.	1.3	6
34	Multiplatform genomic profiling and magnetic resonance imaging identify mechanisms underlying intratumor heterogeneity in meningioma. <i>Nature Communications</i> , 2020, 11, 4803.	5.8	56
35	Grade I meningioma with disseminated bone disease: a rare clinical phenomenon. <i>BMJ Case Reports</i> , 2020, 13, e233708.	0.2	0
36	TERT, a promoter of CNS malignancies. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa025.	0.4	22

#	ARTICLE	IF	CITATIONS
37	Multi-parametric qualitative and quantitative MRI assessment as predictor of histological grading in previously treated meningiomas. <i>Neuroradiology</i> , 2020, 62, 1441-1449.	1.1	6
38	Advances in Molecular Classification and Therapeutic Opportunities in Meningiomas. <i>Current Oncology Reports</i> , 2020, 22, 84.	1.8	17
39	Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 378-387.	0.9	75
40	<i>TERT</i> Promoter Mutation Analysis for Blood-Based Diagnosis and Monitoring of Gliomas. <i>Clinical Cancer Research</i> , 2021, 27, 169-178.	3.2	50
41	Spatial Distribution Patterns of Clinically Relevant TERT Promoter Mutations in Follicular Thyroid Tumors of Uncertain Malignant Potential. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 212-222.	1.2	12
42	<i>TERT</i> promoter mutations in primary and secondary WHO grade III meningioma. <i>Brain Pathology</i> , 2021, 31, 61-69.	2.1	27
43	A Case of Synchronous Radiation-induced Glioblastoma and Meningioma diagnosed 41 Years after Radiation Therapy for Anaplastic Ependymoma. <i>Japanese Journal of Neurosurgery</i> , 2021, 30, 305-311.	0.0	0
44	Craniopharyngiomas, including Recurrent Cases, Lack TERT Promoter Hotspot Mutations. <i>Neurologia Medico-Chirurgica</i> , 2021, 61, 385-391.	1.0	4
45	Clinical and diffusion parameters may noninvasively predict TERT promoter mutation status in grade II meningiomas. <i>Journal of Neuroradiology</i> , 2021, 49, 59-59.	0.6	5
46	Intron 4 hTERT DNA Hypermethylation in Merkel Cell Carcinoma: Frequency, Association with Other Clinico-pathological Features and Prognostic Relevance. <i>Endocrine Pathology</i> , 2021, 32, 385-395.	5.2	4
47	LPCAT1-TERT fusions are uniquely recurrent in epithelioid trophoblastic tumors and positively regulate cell growth. <i>PLoS ONE</i> , 2021, 16, e0250518.	1.1	4
48	Skull Base Tumors: Neuropathology and Clinical implications. <i>Neurosurgery</i> , 2021, 90, .	0.6	3
49	Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential. <i>Frontiers in Immunology</i> , 2021, 12, 682492.	2.2	18
50	High-Throughput Mechanistic Screening of Epigenetic Compounds for the Potential Treatment of Meningiomas. <i>Journal of Clinical Medicine</i> , 2021, 10, 3150.	1.0	5
51	<i>TERT</i> Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional Recurrence. <i>JCO Precision Oncology</i> , 2021, 5, 1259-1269.	1.5	10
52	Human TERT Promoter Mutations in Atypical and Anaplastic Meningiomas. <i>Diagnostics</i> , 2021, 11, 1624.	1.3	3
53	A molecularly integrated grade for meningioma. <i>Neuro-Oncology</i> , 2022, 24, 796-808.	0.6	83
54	A narrative review of targeted therapies in meningioma. <i>Chinese Clinical Oncology</i> , 2020, 9, 76-76.	0.4	15

#	ARTICLE	IF	CITATIONS
55	Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system. <i>Cancer</i> , 2022, 128, 47-58.	2.0	132
57	Malignant transformation of WHO grade I meningiomas after surgery or radiosurgery: systematic review and meta-analysis of observational studies. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa129.	0.4	5
58	Genomic Analysis and Gene-based Medicine for Benign Brain Tumors. <i>Japanese Journal of Neurosurgery</i> , 2020, 29, 536-542.	0.0	0
59	Intratumor Heterogeneity in Hepatocellular Carcinoma: Challenges and Opportunities. <i>Cancers</i> , 2021, 13, 5524.	1.7	15
61	Biology and Treatment of Meningiomas. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 133-146.	0.9	3
62	Implementation of <i>TERT</i> promoter mutations improve prognostication of the WHO classification in meningioma. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	1.8	8
63	Multiple approaches converge on three biological subtypes of meningioma and extract new insights from published studies. <i>Science Advances</i> , 2022, 8, eabm6247.	4.7	33
64	Identification and Management of Aggressive Meningiomas. <i>Frontiers in Oncology</i> , 2022, 12, 851758.	1.3	10
65	The Discrepancy Between Standard Histologic WHO Grading of Meningioma and Molecular Profile: A Single Institution Series. <i>Frontiers in Oncology</i> , 2022, 12, 846232.	1.3	3
66	Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Nasal Cavity, Paranasal Sinuses and Skull Base. <i>Head and Neck Pathology</i> , 2022, 16, 1-18.	1.3	36
67	Correlation of MTAP Immunohistochemistry With CDKN2A Status Assessed by Fluorescence In Situ Hybridization and Clinicopathological Features in CNS WHO Grade 2 and 3 Meningiomas: A Single Center Cohort Study. <i>Journal of Neuropathology and Experimental Neurology</i> , 2022, 81, 117-126.	0.9	11
68	Telomere length and Wnt/ β -catenin pathway in adamantinomatous craniopharyngiomas. <i>European Journal of Endocrinology</i> , 2022, 187, 219-230.	1.9	3
69	Potential Molecular Mechanisms of Recurrent and Progressive Meningiomas: A Review of the Latest Literature. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
70	Intratumor and informatic heterogeneity influence meningioma molecular classification. <i>Acta Neuropathologica</i> , 2022, 144, 579-583.	3.9	10
71	2021 WHO classification of tumours of the central nervous system: a review for the neuroradiologist. <i>Neuroradiology</i> , 2022, 64, 1919-1950.	1.1	29
72	Molecular determinants of outcomes in meningiomas. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
73	Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	8
74	Primary Intracranial Spindle Cell Sarcoma, <i>DICER1</i> -Mutant, with <i>MDM2</i> Amplification Diagnosed on the Basis of Extensive Molecular Profiling. <i>Clinical Medicine Insights: Case Reports</i> , 2022, 15, 117954762211311.	0.3	3

#	ARTICLE	IF	CITATIONS
75	Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic <i>NF2</i> Mutations. <i>Journal of Clinical Oncology</i> , 2023, 41, 618-628.	0.8	27
76	Integration of molecular pathology with histopathology to accurately evaluate the biological behaviour of WHO grade 2 meningiomas and patient prognosis. <i>Journal of Neuro-Oncology</i> , 0, , .	1.4	0
77	Malignant meningioma. <i>Apmis</i> , 2022, 130, 1-58.	0.9	1
78	Importancia pronóstica de las mutaciones del gen promotor de la transcriptasa inversa de la telomerasa en los meningiomas de alto grado. <i>Biomedica</i> , 2022, 42, 574-590.	0.3	0
79	The TERT Promoter: A Key Player in the Fight for Cancer Cell Immortality. <i>Biochemistry (Moscow)</i> , 2023, 88, S21-S38.	0.7	0
80	DNA methylation provides diagnostic value for meningioma recurrence in clinical practice. <i>Acta Neurochirurgica</i> , 2023, 165, 1323-1331.	0.9	2
81	Novel Systemic Approaches for the Management of Meningiomas. <i>Neurosurgery Clinics of North America</i> , 2023, , .	0.8	1
82	Review of meningioma diagnosis and management. <i>Egyptian Journal of Neurosurgery</i> , 2023, 38, .	0.2	1
84	Genomic Landscape of Meningiomas. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 137-158.	0.8	0
86	Commentary: Novel Postoperative Serum Biomarkers in Atypical Meningiomas: A Multicenter Study. <i>Neurosurgery</i> , 2023, 93, e129-e130.	0.6	0